These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

162 related items for PubMed ID: 30507748

  • 1. Sensitivity of fluorine-18-fluoromethylcholine PET/CT to prostate-specific antigen over different plasma levels: a retrospective study in a cohort of 192 patients with prostate cancer.
    Giovacchini G, Giovannini E, Borsò E, Lazzeri P, Riondato M, Leoncini R, Duce V, Conti E, Picchio M, Ciarmiello A.
    Nucl Med Commun; 2019 Mar; 40(3):258-263. PubMed ID: 30507748
    [Abstract] [Full Text] [Related]

  • 2. Oligometastatic recurrent prostate cancer detects by fluorine-18-choline positron emission tomography/computed tomography in patients with prostate-specific antigen levels of up to 5 ng/ml.
    Evangelista L, Cuppari L, Guttilla A, Gardi M, Agostini A, Ruggera L, Basso U, Saladini G.
    Nucl Med Commun; 2018 Mar; 39(3):260-267. PubMed ID: 29381584
    [Abstract] [Full Text] [Related]

  • 3. Influence of trigger PSA and PSA kinetics on 11C-Choline PET/CT detection rate in patients with biochemical relapse after radical prostatectomy.
    Castellucci P, Fuccio C, Nanni C, Santi I, Rizzello A, Lodi F, Franceschelli A, Martorana G, Manferrari F, Fanti S.
    J Nucl Med; 2009 Sep; 50(9):1394-400. PubMed ID: 19690023
    [Abstract] [Full Text] [Related]

  • 4. Prospective Comparison of 18F-Fluoromethylcholine Versus 68Ga-PSMA PET/CT in Prostate Cancer Patients Who Have Rising PSA After Curative Treatment and Are Being Considered for Targeted Therapy.
    Morigi JJ, Stricker PD, van Leeuwen PJ, Tang R, Ho B, Nguyen Q, Hruby G, Fogarty G, Jagavkar R, Kneebone A, Hickey A, Fanti S, Tarlinton L, Emmett L.
    J Nucl Med; 2015 Aug; 56(8):1185-90. PubMed ID: 26112024
    [Abstract] [Full Text] [Related]

  • 5. Clinical utility of (18)F-fluorocholine positron-emission tomography/computed tomography (PET/CT) in biochemical relapse of prostate cancer after radical treatment: results of a multicentre study.
    Rodado-Marina S, Coronado-Poggio M, García-Vicente AM, García-Garzón JR, Alonso-Farto JC, de la Jara AC, Maldonado-Suárez A, Rodríguez-Fernández A.
    BJU Int; 2015 Jun; 115(6):874-83. PubMed ID: 25307619
    [Abstract] [Full Text] [Related]

  • 6. Positron emission tomography/computed tomography with F-18-fluorocholine for restaging of prostate cancer patients: meaningful at PSA < 5 ng/ml?
    Heinisch M, Dirisamer A, Loidl W, Stoiber F, Gruy B, Haim S, Langsteger W.
    Mol Imaging Biol; 2006 Jun; 8(1):43-8. PubMed ID: 16315004
    [Abstract] [Full Text] [Related]

  • 7. PET/CT with (18)F-choline after radical prostatectomy in patients with PSA ≤2 ng/ml. Can PSA velocity and PSA doubling time help in patient selection?
    Chiaravalloti A, Di Biagio D, Tavolozza M, Calabria F, Schillaci O.
    Eur J Nucl Med Mol Imaging; 2016 Jul; 43(8):1418-24. PubMed ID: 26791373
    [Abstract] [Full Text] [Related]

  • 8. Impact of 18F-choline PET/CT in prostate cancer patients with biochemical recurrence: influence of androgen deprivation therapy and correlation with PSA kinetics.
    Beheshti M, Haim S, Zakavi R, Steinmair M, Waldenberger P, Kunit T, Nader M, Langsteger W, Loidl W.
    J Nucl Med; 2013 Jun; 54(6):833-40. PubMed ID: 23559588
    [Abstract] [Full Text] [Related]

  • 9. Role of PET-CT with 18F-fluorocholine in biochemical recurrence after treatment of prostate cancer with curative intent.
    Puche-Sanz I, Triviño-Ibáñez E, Vázquez-Alonso F, Llamas-Elvira JM, Cózar-Olmo JM, Rodríguez-Fernández A.
    Actas Urol Esp; 2017 Sep; 41(7):437-444. PubMed ID: 28389027
    [Abstract] [Full Text] [Related]

  • 10. Predictive factors of [(11)C]choline PET/CT in patients with biochemical failure after radical prostatectomy.
    Giovacchini G, Picchio M, Coradeschi E, Bettinardi V, Gianolli L, Scattoni V, Cozzarini C, Di Muzio N, Rigatti P, Fazio F, Messa C.
    Eur J Nucl Med Mol Imaging; 2010 Feb; 37(2):301-9. PubMed ID: 19756592
    [Abstract] [Full Text] [Related]

  • 11. Early biochemical relapse after radical prostatectomy: which prostate cancer patients may benefit from a restaging 11C-Choline PET/CT scan before salvage radiation therapy?
    Castellucci P, Ceci F, Graziani T, Schiavina R, Brunocilla E, Mazzarotto R, Pettinato C, Celli M, Lodi F, Fanti S.
    J Nucl Med; 2014 Sep; 55(9):1424-9. PubMed ID: 24935990
    [Abstract] [Full Text] [Related]

  • 12. Usefulness of 18F-fluorocoline PET/CT in prostate cancer patients with biochemical recurrence: Influence of PSA kinetics and hormone therapy.
    Triviño-Ibáñez EM, Puche-Sanz I, Gómez-Río M, Cózar Olmo JM, Llamas-Elvira JM, Rodríguez-Fernández A.
    Med Clin (Barc); 2019 Jul 19; 153(2):56-62. PubMed ID: 30660434
    [Abstract] [Full Text] [Related]

  • 13. Gleason score at diagnosis predicts the rate of detection of 18F-choline PET/CT performed when biochemical evidence indicates recurrence of prostate cancer: experience with 1,000 patients.
    Cimitan M, Evangelista L, Hodolič M, Mariani G, Baseric T, Bodanza V, Saladini G, Volterrani D, Cervino AR, Gregianin M, Puccini G, Guidoccio F, Fettich J, Borsatti E.
    J Nucl Med; 2015 Feb 19; 56(2):209-15. PubMed ID: 25552670
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Role of 18F-Choline PET/CT in guiding biopsy in patients with risen PSA levels and previous negative biopsy for prostate cancer.
    Jiménez Londoño GA, García Vicente AM, Amo-Salas M, Fúnez Mayorga F, López Guerrero MA, Talavera Rubio MP, Gutierrez Martin P, González García B, de la Torre Pérez JA, Soriano Castrejón ÁM.
    Rev Esp Med Nucl Imagen Mol; 2017 Feb 19; 36(4):241-246. PubMed ID: 28330596
    [Abstract] [Full Text] [Related]

  • 16. Significant increase in detection of prostate cancer recurrence following radical prostatectomy with an early imaging acquisition protocol with ¹⁸F-fluorocholine positron emission tomography/computed tomography.
    Simone G, Di Pierro GB, Papalia R, Sciuto R, Rea S, Ferriero M, Guaglianone S, Maini CL, Gallucci M.
    World J Urol; 2015 Oct 19; 33(10):1511-8. PubMed ID: 25577130
    [Abstract] [Full Text] [Related]

  • 17. Pairwise comparison of 18F-FDG and 18F-FCH PET/CT in prostate cancer patients with rising PSA and known or suspected second malignancy.
    How Kit N, Dugué AE, Sevin E, Allouache N, Lesaunier F, Joly F, Aide N.
    Nucl Med Commun; 2016 Apr 19; 37(4):348-55. PubMed ID: 26642435
    [Abstract] [Full Text] [Related]

  • 18. (11)C-Choline PET/CT for restaging prostate cancer. Results from 4,426 scans in a single-centre patient series.
    Graziani T, Ceci F, Castellucci P, Polverari G, Lima GM, Lodi F, Morganti AG, Ardizzoni A, Schiavina R, Fanti S.
    Eur J Nucl Med Mol Imaging; 2016 Oct 19; 43(11):1971-9. PubMed ID: 27277279
    [Abstract] [Full Text] [Related]

  • 19. [18F]fluorocholine PET/CT imaging for the detection of recurrent prostate cancer at PSA relapse: experience in 100 consecutive patients.
    Cimitan M, Bortolus R, Morassut S, Canzonieri V, Garbeglio A, Baresic T, Borsatti E, Drigo A, Trovò MG.
    Eur J Nucl Med Mol Imaging; 2006 Dec 19; 33(12):1387-98. PubMed ID: 16865395
    [Abstract] [Full Text] [Related]

  • 20. Evaluation of extraprostatic disease in the staging of prostate cancer by F-18 choline PET/CT: can PSA and PSA density help in patient selection?
    Calabria F, Chiaravalloti A, Tavolozza M, Ragano-Caracciolo C, Schillaci O.
    Nucl Med Commun; 2013 Aug 19; 34(8):733-40. PubMed ID: 23680652
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.